RCM
FBLG icon

Requisite Capital Management’s FibroBiologics FBLG Stock Holding History

Requisite Capital Management’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,486
Closed -$24.7K – 129
2025
Q4 		$24.7K Hold
5,486
– – ﹤0.01% 123
2025
Q3 		$59.9K Hold
5,486
– – 0.01% 360
2025
Q2 		$68.3K Hold
5,486
– – 0.01% 85
2025
Q1 		$98.7K Hold
5,486
– – 0.02% 84
2024
Q4 		$219K Hold
5,486
– – 0.04% 89
2024
Q3 		$339K Hold
5,486
– – 0.07% 55
2024
Q2 		$547K Buy
+5,486
New +$1.05M 0.12% 43

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Requisite Capital Management's FBLG Position: Q1 2026 in Review

Requisite Capital Management sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 5,486 shares — an estimated $24.7K sold.

Requisite Capital Management first reported a position in FBLG in Q2 2024 and held it in 7 quarters. The position peaked at $547K in Q2 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Requisite Capital Management reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
  • Requisite Capital Management sold 5,486 FibroBiologics shares in Q1 2026, an estimated $24.7K.
  • Requisite Capital Management first reported a position in FibroBiologics in Q2 2024 and held it in 7 quarters.
  • Requisite Capital Management's FibroBiologics position peaked at $547K in Q2 2024.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Requisite Capital Management's 13F filing for Q1 2026, filed 14 May 2026.